Edesa Biotech reports Q1 net loss of $1.7M; secures up to C$23M govt funding for ARDS drug

Edesa Biotech, Inc.

Net loss $1.7M ($0.54/share) vs $2.3M ($0.89) YoY; operating expenses down to $1.9M from $2.4M.
Cash and equivalents $4.3M at Dec 31, 2023; working capital $3.4M.
Secured up to C$23M from Canadian government for EB05 ARDS Phase 3; regulators approved harmonized US/Canada trial.
Planning Phase 2 for vitiligo (anti-CXCL10 mAb) and pulmonary fibrosis (EB05); seeking partnerships for dermatitis candidate EB01.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Edesa Biotech, Inc. reported the three months ended December 31, 2023 results: net income a net loss of $1.7 million, or $0.54 per common share, EPS $0.54 per common share.

Period: the three months ended December 31, 2023
Net income: a net loss of $1.7 million, or $0.54 per common share
EPS: $0.54 per common share
Result: reported results

Exact text from the filing

Edesa reported a net loss of $1.7 million, or $0.54 per common share

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Edesa Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-001539

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.